A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Phase I: A study to see what doses of Enzastaurin and Erlotinib are best tolerated by
participants with solid tumor cancer.
Phase II: A study to see how long participants with non-small cell lung cancer (NSCLC)
treated with Enzastaurin and Erlotinib live.